Recombinant Dengue Virus Serotype 2 VLP
Specification
Related Products
| Cat#: |
DEN-175 |
| Product Name: |
Recombinant Dengue Virus Serotype 2 VLP |
| Description: |
Dengue Virus Serotype 2 VLP (Virus-Like Particle) is a new, unique product that has been developed in response to the need for highly immunogenic, concentrated Dengue antigens for use in Dengue focussed disease research and vaccine development (including use as an immunogen). |
| Gene: |
VLP |
| Species: |
DENV Serotype 2 |
| Source: |
HEK293 |
| Synonyms: |
DENV Serotype 2 VLP |
| Formulation: |
10mM sodium phosphate, 20mM sodium citrate, 154mM sodium chloride, pH7.4 |
| Stability: |
At +4 centigrade: 1 week.
At -80 centigrade: 1 year. |
| Purity: |
>95% pure by SDS-PAGE |
| Storage: |
Short Term Storage: +4 centigrade
Long Term Storage: -80 centigrade
Avoid excessive mixing or shocking to prevent aggregation. Long term storage above -80 centigrade may result in aggregate formation and/or degradation. |
| Notes: |
This product is intended for research and manufacturing uses only. It is not a diagnostic device. The user assumes all responsibility for care, custody and control of the material, including its disposal, in accordance with all regulations. |
| Protein Length: |
115-800 |
| Freezing: |
Can be frozen, but avoid multiple freeze/thaw cycles. |
| Sequence Strain: |
Thailand/16681/84 |
| Background: |
Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.
With more than one-third of the world's population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics (ref WHO for Guidelines for Diagnosis, Treatment, Prevention & Control, 2009) As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus. Dengue Virus Serotype 1, Serotype 3 and Serotype 4 VLPs are also now available. |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
